Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCedars-Sinai Medical Center
About this trial
This study encompasses the maintenance and utilization of a repository of samples from patients with cerebrovascular disease and stroke. The types of tissue taken are blood, cerebrospinal fluid (CSF), tissue, and microdialysis samples. Future analysis of these samples can potentially help investigators to better categorize groups of patients, understand the underlying etiology of these pathologies, identify markers that are associated with favorable or poor outcomes, and track changes that occur during the natural course of the disease or with treatment. This is a prospective observational study which will use samples from such patients to create this library which can be used to explore these questions in the future.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
All patients diagnosed with cerebral vascular disease, regardless of gender, age, ethnicity/race, stage of disease or treatment, are eligible.
Expected availability of clinical follow up data
Participants must be willing to provide written, informed consent obtained in accordance with institutional and federal guidelines.
Disqualifiers
Pregnant women are excluded from the study.
Trial population
All patients diagnosed with cerebrovascular disease. This includes both non-surgical patients (such medically managed ischemic stroke, aneurysms, moyamoya disease, arteriovenous malformation, hemorrhagic stroke, etc.) and surgically treated patients (patients with aneurysm coiling or clipping, arteriovenous malformation resection, direct or indirect revascularization procedures for ischemia, etc.).
Trial design
Design model
Other
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
900 Participants
are grouped into 1 trial groupGroup A: Repository Group
Trial outcomes
Primary outcomes
1
Change in modified Rankin Scale (mRS) score
Time frame
Baseline, 1 Month, 3 Months, and 6 Months2
Change in NIH Stroke Scale score
Time frame
Baseline, 1 Month, 3 Months, and 6 Months3
Change in Barthel Index
Time frame
Baseline, 1 Month, 3 Months, and 6 Months4
Change in Montreal Cognitive Assessment test score
Time frame
Baseline, 1 Month, 3 Months, and 6 MonthsSecondary outcomes
1
Change in Angiographic Neovascularization
Analyzed in digital subtraction angiography (DSA) images
Time frame
Baseline and 6 Months2
Change in Angiogenic Factor Measurements
Measured in blood, CSF, microdialysis samples, and tissue
Time frame
Baseline, 1 Month, 3 Months, 6 MonthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov